|
[1] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016:A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):383-403.
|
|
[2] COOKE GS, ANDRIEUX-MEYER I, APPLEGATE TL, et al.Accelerating the elimination of viral hepatitis:A Lancet Gastroenterology&Hepatology Commission[J]. Lancet Gastroenterol Hepatol, 2019, 4(2):135-184.
|
|
[3] TANG LSY, COVERT E, WILSON E, et al. Chronic hepatitis B infection:A review[J]. JAMA, 2018, 319(17):1802-1813.
|
|
[4] YUEN MF, CHEN DS, DUSHEIKO GM, et al. Hepatitis B virus infection[J]. Nat Rev Dis Primers, 2018, 4:18035.
|
|
[5] REVILL PA, CHISARI FV, BLOCK JM, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol,2019, 4(7):545-558.
|
|
[6] FANNING GC, ZOULIM F, HOU J, et al. Therapeutic strategies for hepatitis B virus infection:Towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11):827-844.
|
|
[7] LANCET T. Carving a new path to a hepatitis B cure[J]. Lancet, 2020, 394(10216):2202.
|
|
[8] MARTINEZ MG, TESTONI B, ZOULIM F. Biological basis for functional cure of chronic hepatitis B[J]. J Viral Hepat, 2019,26(7):786-794.
|
|
[9] LUCIFORA J, XIA Y, REISINGER F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science, 2014, 343(6176):1221-1228.
|
|
[10] LOK AS, ZOULIM F, DUSHEIKO G, et al. Hepatitis B cure:From discovery to regulatory approval[J]. Hepatology, 2017,66(4):1296-1313.
|
|
[11] BERTOLETTI A, LE BERT N. Immunotherapy for chronic hepatitis B virus infection[J]. Gut Liver, 2018, 12(5):497-507.
|
|
[12] PARK JJ, WONG DK, WAHED AS, et al. Hepatitis B virusspecific and global T-cell dysfunction in chronic hepatitis B[J]. Gastroenterology, 2016, 150(3):684-695. e5.
|
|
[13] HU J, PROTZER U, SIDDIQUI A. Revisiting hepatitis B virus:Challenges of curative therapies[J]. J Virol, 2019, 93(20):e01032-19.
|
|
[14] NING Q, WU D, WANG GQ, et al. Roadmap to functional cure of chronic hepatitis B:An expert consensus[J]. J Viral Hepat, 2019, 26(10):1146-1155.
|
|
[15] European Association for the Study of the Liver. EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2):370-398.
|
|
[16] WANG XY, WEN YM. A"sandwich"strategy for functional cure of chronic hepatitis B[J]. Emerg Microbes Infect, 2018,7(1):91.
|
|
[17] ZOULIM F. Inhibition of hepatitis B virus gene expression:A step towards functional cure[J]. J Hepatol, 2018, 68(3):386-388.
|
|
[18] LIU J, JIANG M, MA Z, et al. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+T cell immunity in vitro[J]. J Immunol, 2013, 191(12):6178-6190.
|
|
[19] LIU J, YU Q, WU W, et al. TLR2 stimulation strengthens intrahepatic myeloid-derived cell-mediated T cell tolerance through inducing Kupffer cell expansion and IL-10 production[J]. J Immunol, 2018, 200(7):2341-2351.
|
|
[20] LANFORD RE, GUERRA B, CHAVEZ D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J]. Gastroenterology, 2013, 144(7):1508-1517,1517. e1-10.
|
|
[21] JO J, TAN AT, USSHER JE, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver[J]. PLoS Pathog, 2014, 10(6):e1004210.
|
|
[22] WALSH R, HAMMOND R, JACKSON K, et al. PS-160-effects of SB9200(Inarigivir)therapy on immune responses in patients with chronic hepatitis B[J]. J Hepatol, 2018, 68(1):s89.
|
|
[23] SATO S, LI K, KAMEYAMA T, et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus[J]. Immunity, 2015, 42(1):123-132.
|
|
[24] HUANG S, ZOU S, CHEN M, et al. Local Stimulation of liver sinusoidal endothelial cells with a NOD1 agonist activates T cells and suppresses hepatitis B virus replication in mice[J].J Immunol, 2018, 200(9):3170-3179.
|
|
[25] YANG S, WANG L, PAN W, et al. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance[J]. J Hepatol,2019, 71(4):685-698.
|
|
[26] CHENG X, XIA Y, SERTI E, et al. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages[J]. Hepatology, 2017, 66(6):1779-1793.
|
|
[27] BÉNÉCHET AP, de SIMONE G, di LUCIA P, et al. Dynamics and genomic landscape of CD8+T cells undergoing hepatic priming[J]. Nature, 2019, 574(7777):200-205.
|
|
[28] BURTON AR, PALLETT LJ, MCCOY LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B[J]. J Clin Invest, 2018, 128(10):4588-4603.
|
|
[29] PHILLIPS S, MISTRY S, RIVA A, et al. Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients[J]. Front Immunol, 2017, 8:621.
|
|
[30] SALIMZADEH L, LE BERT N, DUTERTRE CA, et al. PD-1blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection[J]. J Clin Invest, 2018,128(10):4573-4587.
|
|
[31] GUO WN, ZHU B, AI L, et al. Animal models for the study of hepatitis B virus infection[J]. Zool Res, 2018, 39(1):25-31.
|
|
[32] MENG Z, ZHANG X, PEI R, et al. Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection[J]. Antiviral Res, 2016, 125:14-24.
|
|
[33] MA Z, ZHANG E, GAO S, et al. Toward a functional cure for hepatitis B:The rationale and challenges for therapeutic targeting of the B cell immune response[J]. Front Immunol, 2019,10:2308.
|
|
[34] BURTON AR, PALLETT LJ, MCCOY LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B[J]. J Clin Invest, 2018, 128(10):4588-4603.
|
|
[35] NEUMANN-HAEFELIN C, THIMME R. Entering the spotlight:Hepatitis B surface antigen-specific B cells[J]. J Clin Invest, 2018, 128(10):4257-4259.
|
|
[36] SETO WK, YUEN MF. New pharmacological approaches to a functional cure of hepatitis B[J]. Clin Liver Dis(Hoboken),2016, 8(4):83-88.
|
|
[37] LI MH, YI W, ZHANG L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy[J]. J Viral Hepat, 2019, 26(Suppl 1):32-41.
|
|
[38] TESTONI B, LEBOSSÉF, SCHOLTES C, et al. Serum hepatitis B core-related antigen(HBcrAg)correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(4):615-625.
|
DownLoad: